On October 20, Haixi Pharma held its H-share listing ceremony at The Stock Exchange of Hong Kong Limited (HKEX), marking its official debut on the Main Board. The stock is traded under the short name Haixi Pharma with the stock code shturl.c. As an innovative pharmaceutical enterprise, the Company has stepped onto the international capital market and embarked on a new global development journey underpinned by its strategy: generic drugs consolidate fundamentals and empower growth, while innovative drugs spearhead breakthroughs.
In this global offering, the Company issued 11,500,000 H-shares, accounting for 14.61% of the total share capital post-listing. The offering price was set at HK$86.40 per share, translating to a total offering size of approximately HK$990 million. The offering garnered overwhelming market enthusiasm, with the Hong Kong public tranche recording an over-subscription rate of 3,165.1 times. This remarkable figure fully demonstrates strong recognition from investors in Hong Kong’s capital market for the Company’s core value and long-term growth potential.
"Today, I am delighted to stand with all of you to witness this exciting milestone as Fujian Haixi Pharmaceutical Innovation Co., Ltd. lists on HKEX," said Dr. Kang Xinshan, Founder and Chairman of the Company, brimming with joy at the listing ceremony. He reflected fondly on the Company’s journey: "Over the past thirteen years, we have forged ahead through challenges. What started as a R&D-focused startup has evolved into a fully integrated listed pharmaceutical enterprise covering the entire industrial chain of research & development, production and sales. None of this would have been possible without the unwavering trust of our shareholders, the strong support from HKEX, the Securities and Futures Commission of Hong Kong and all intermediary institutions. Most importantly, I would like to thank our dedicated team for their perseverance and hard work. It is everyone’s joint efforts that have brought Haixi Pharma to where it stands today."
Dr. Kang further emphasized that the Company has long adhered to its dual-track development philosophy: Generic Drugs Fuel Innovation, Innovation Powers the Future. Having witnessed the transformation of China’s pharmaceutical industry—from breakthroughs in generics to the global expansion of innovative drugs—Haixi Pharma will build on this listing milestone and uphold its core values of Innovation, Integrity, Sharing and Benevolence. The Company will focus on key therapeutic areas including cardiovascular diseases, gastroenterology, oncology and ophthalmology, and press ahead vigorously with its innovative drug business.
It will accelerate the clinical development and commercialization of flagship pipeline candidates, including C019199—the world’s first potential breakthrough therapy for osteosarcoma—and HXP056, the Company’s first oral drug for fundus diseases. Capitalizing on its differentiated strengths of generics generating steady cash flow and innovative drugs driving technological advancement, the Company will translate cutting-edge technologies into high-quality medicines to address unmet clinical needs and benefit patients worldwide.
Looking ahead, Haixi Pharma will take Hong Kong as its international hub to further optimize corporate governance and expand its presence across domestic and global markets, striving to become a trusted value partner for the international capital community. The Company aims to set a benchmark as a global pharmaceutical player excelling at integrating generics and innovative drugs. It will deliver superior treatment solutions to safeguard human health, and sustain solid business performance to reward the trust and expectations of all stakeholders. Moving forward, Haixi Pharma will work alongside global investors to realize the grand vision of making innovative medicines accessible to people across the globe.
